Roivant Sciences

Oviva Therapeutics Appoints Rachel Rimsky Rubin as Chief Operating Officer

Retrieved on: 
Tuesday, September 12, 2023
Market for Alternative Investment, Therapy, Alternative investment, Biomedical Research, Woman, GAM, Roivant Sciences, Deutsche Bank, IVF, HOME Investment Partnerships Program, Goldman Sachs, Acquisition, Growth, Entrepreneurship, Health, Cornell University, Female, Management, Investment

NEW YORK, Sept. 12, 2023 /PRNewswire/ -- Oviva Therapeutics, a premier biotech company dedicated to addressing the vast unmet need in women's health by developing first-in-class therapeutics to preserve ovarian function and consequently extend female healthspan, today announced the appointment of Rachel Rimsky Rubin as its new Chief Operating Officer (COO), effective as of September 5, 2023.

Key Points: 
  • NEW YORK, Sept. 12, 2023 /PRNewswire/ -- Oviva Therapeutics, a premier biotech company dedicated to addressing the vast unmet need in women's health by developing first-in-class therapeutics to preserve ovarian function and consequently extend female healthspan, today announced the appointment of Rachel Rimsky Rubin as its new Chief Operating Officer (COO), effective as of September 5, 2023.
  • Prior to joining Oviva, Rubin served as Vice President of Investments and Programs at Roivant Social Ventures.
  • "We are thrilled to welcome Rachel Rimsky Rubin to the Oviva team as our first Chief Operating Officer," said Daisy Robinton, Co-Founder and CEO of Oviva Therapeutics.
  • In her role, Rubin will build infrastructure and implement company strategy to usher Oviva through its next phase of growth.

Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants

Retrieved on: 
Thursday, August 17, 2023
Transfer, Exercise, Indian stock exchange, Redemption, Public, Sale, Form S-3, Form, Security (finance), Common, Bank, Warrant, Roivant Sciences

BASEL, Switzerland and LONDON and NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the “Redemption Fair Market Value” to be used in connection with the previously announced redemption of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”).

Key Points: 
  • BASEL, Switzerland and LONDON and NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the “Redemption Fair Market Value” to be used in connection with the previously announced redemption of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”).
  • The Warrant Agent previously delivered the notice of redemption (the “Notice of Redemption”) to each of the registered holders of the outstanding Warrants on behalf of Roivant.
  • Roivant has directed the Warrant Agent to deliver a notice (the “Notice of Redemption Fair Market Value”) on behalf of Roivant to each of the registered holders of the outstanding Warrants informing holders:
    that the Redemption Fair Market Value is $11.35; and
    as a result, holders who elect to exercise their Warrants on a “cashless basis” (a “Make-Whole Exercise”) prior to the Redemption Date will be entitled to receive approximately 0.2495 Common Shares per Warrant exercised.
  • For copies of the Notice of Redemption and the Notice of Redemption Fair Market Value, please visit our investor relations website at https://investor.roivant.com/ .

Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update

Retrieved on: 
Monday, August 14, 2023
Sarcoidosis, Lupus, CIDP, SG, DM, IQVIA, Calendar, Myasthenia gravis, NIU, Prescription, Atopic dermatitis, Research, GD, SLE, Pharmacy, Ulcerative colitis, Psoriasis, MDS, Acquisition, Patient, Transfusion-dependent anemia, Drug discovery, R, FDA, Safety, TED, Pharmaceutical industry, Life insurance, Cryptocurrency, Dermatomyositis, Roivant Sciences

Dermavant: For the first quarter ended June 30, 2023, Roivant reported VTAMA net product revenue of $16.7M, representing a 26% gross-to-net yield for the quarter.

Key Points: 
  • Dermavant: For the first quarter ended June 30, 2023, Roivant reported VTAMA net product revenue of $16.7M, representing a 26% gross-to-net yield for the quarter.
  • First Quarter Ended June 30, 2023, Financial Summary
    As of June 30, 2023, the company had consolidated cash, cash equivalents and restricted cash of $1.4 billion.
  • Net loss was $327.8 million for the three months ended June 30, 2023, compared to $353.8 million for the three months ended June 30, 2022.
  • Non-GAAP net loss was $211.5 million for the three months ended June 30, 2023, compared to $210.7 million for the three months ended June 30, 2022.

Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress

Retrieved on: 
Thursday, August 10, 2023
Insurance, ASH, Cholangiocarcinoma, American Society of Clinical Oncology, Patient, EGFR, International Financial Reporting Standards, IASB, Hematology, International Accounting Standards Board, NK, Genentech, Lung cancer, 2023 International Conference on Climate Resilient Pakistan, Cytokine release syndrome, FDA, IND, Conference, Book, Safety, Hodgkin lymphoma, Interim, International, MSS, Non-Hodgkin lymphoma, Cancer, Record, NSCLC, Cell, Acute myeloid leukemia, Colorectal cancer, Roivant Sciences, HL, CR, Webcast, Research, ORR, PTCL, PK, CRC, Bank statement, Lymphoma, Clinical trial, NHL, EDT, CFGB-FM, Trial of the century, AML, Financial toxicity, Society, Pharmaceutical industry, Audit, Cryptocurrency, Euro, Affimer

AFM24 combinations: Affimed plans to report data from the combination with atezolizumab in the fourth quarter 2023; data from combination study with SNK01 were presented at ASCO Breakthrough.

Key Points: 
  • AFM24 combinations: Affimed plans to report data from the combination with atezolizumab in the fourth quarter 2023; data from combination study with SNK01 were presented at ASCO Breakthrough.
  • HEIDELBERG, Germany, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the second quarter of 2023.
  • Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB.
  • Affimed will host a conference call and webcast on August 10, 2023, at 8:30 a.m. EDT / 14:30 CET to discuss second quarter 2023 financial results and corporate developments.

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Retrieved on: 
Wednesday, August 9, 2023
Research, FDA, Clinical Trials, Biotechnology, Pharmaceutical, Health, Optical, Science, Oncology, Other Science, Senior, SC, NMIBC, Drug, Vanderbilt University Medical Center, Bladder cancer, DRS, Melanoma, Quality, Incidence, CM, Patient, Division, Roivant Sciences, VDC, Growth, Regulatory affairs, SVP, Visual acuity, Fast track (FDA), Safety, Pharmaceutical industry, Nursing, Medical imaging, Medical device, Cryptocurrency

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the second quarter ended June 30, 2023, and provided clinical development and operational highlights.

Key Points: 
  • Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the second quarter ended June 30, 2023, and provided clinical development and operational highlights.
  • The first patient is expected to be dosed in the second half of 2023.
  • Strengthened the clinical leadership team with the following key appointments:
    Dr. Bruce Brown joined Aura as Therapeutic Area Head Urologic Oncology.
  • As of June 30, 2023, Aura had cash and cash equivalents and marketable securities totaling $162.0 million.

Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover

Retrieved on: 
Tuesday, August 8, 2023
Temple University, Drug discovery, Head, University of Bristol, Merck, Commercial Operating System, Biotechnology Innovation Organization, Otsuka Pharmaceutical, BIO, University, Ōtsuka, GW, Honours degree, GW Pharmaceuticals, Genetic distance, Corcept Therapeutics, Organization, UCB, Villalba v Merrill Lynch & Co Inc, Cannabidiol, Mazda North American Operations, Drexel University, Epilepsy, Neuroscience, INSEAD, Justin, Roivant Sciences, Therapy, Doctor of Philosophy, Sale, Defense Innovation Board, DSM-IV codes, Jazz Pharmaceuticals, University of Edinburgh, Pharmaceutical industry, Xenon

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced two new appointments to its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced two new appointments to its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover.
  • Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “On behalf of our Board of Directors, I am delighted to welcome Gillian and Justin to our Board.
  • Gillian brings a vast knowledge of commercializing novel medicines and leading successful neuroscience franchises at large pharmaceutical companies.
  • Mr. Gover currently serves on the Board of Directors for CURE Epilepsy and Rady Children’s Institute for Genomic Medicine.

Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023

Retrieved on: 
Thursday, August 3, 2023
Webcast, Cryptocurrency, Online shopping, Video game, Roivant Sciences

BASEL, Switzerland and LONDON and NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m.

Key Points: 
  • BASEL, Switzerland and LONDON and NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m.
  • ET on Monday, August 14, 2023, to report its financial results for the quarter ended June 30, 2023, and provide a business update.
  • To access the conference call by phone, please register online using this registration link .
  • The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Thursday, August 3, 2023
EASL, Arm, Drug development, Therapy, General counsel, Virology, NA, Clinical trial, Drug, Immunity, CTA, Viral, Roivant Sciences, Research, CFBV, RNA, Doctor of Philosophy, Arbutus, Congress, Medsafe, HBsAg, Investigational New Drug, Patent, MD, Patient, Investment, Immune system, Chief medical informatics officer, RNA interference, European Association for the Study of the Liver, PD-1, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, HBV, Food, Safety, Nivolumab, Pharmaceutical industry, Vaccine, Tutoring, Liver

We plan to provide a further update on this clinical trial when we have additional meaningful patient data.

Key Points: 
  • We plan to provide a further update on this clinical trial when we have additional meaningful patient data.
  • Preliminary data from patients in the clinical trial are expected in the second half of 2023.
  • The Phase 1 clinical trial with AB-161 is on-going with single-ascending dose data expected in the second half of 2023.
  • We expect to nominate an nsp12 inhibitor clinical candidate and initiate IND-enabling studies in the second half of 2023.

Roivant Announces Redemption of Outstanding Warrants

Retrieved on: 
Wednesday, August 2, 2023
Transfer, Exercise, Indian stock exchange, Reference, Private, Public, Sale, Form S-3, Form, Dietary Reference Values, Security (finance), Redemption, Warrant, Roivant Sciences

BASEL, Switzerland and LONDON and NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will redeem all of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”) to purchase Roivant’s common shares (the “Common Shares”) pursuant to its Warrant Agreement dated September 30, 2021 with Equiniti Trust Company, LLC (formerly American Stock Transfer & Trust Company, LLC) as successor warrant agent (the “Warrant Agent”) (the “Warrant Agreement”), that remain outstanding following 5:00 p.m. New York City Time on September 1, 2023 (the “Redemption Date”) for a redemption price of $0.10 per Warrant (the “Redemption Price”).

Key Points: 
  • BASEL, Switzerland and LONDON and NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will redeem all of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”) to purchase Roivant’s common shares (the “Common Shares”) pursuant to its Warrant Agreement dated September 30, 2021 with Equiniti Trust Company, LLC (formerly American Stock Transfer & Trust Company, LLC) as successor warrant agent (the “Warrant Agent”) (the “Warrant Agreement”), that remain outstanding following 5:00 p.m. New York City Time on September 1, 2023 (the “Redemption Date”) for a redemption price of $0.10 per Warrant (the “Redemption Price”).
  • The Warrant Agent has delivered the notice of redemption (the “Notice of Redemption”) to each of the registered holders of the outstanding Warrants on behalf of Roivant.
  • Roivant will inform holders of Warrants of the Redemption Fair Market Value no later than one (1) business day after the ten (10) trading day period ends.
  • Any Warrants that remain unexercised at 5:00 p.m. New York City Time on the Redemption Date will be delisted, void and no longer exercisable, and the holders of unexercised Warrants will have no rights with respect to those Warrants, except to receive the Redemption Price.

Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease

Retrieved on: 
Thursday, July 27, 2023
CD, Therapy, Inflammatory Bowel Diseases, IBD, Disease, Amsterdam, Inflammation, Fibrosis, Vant, Patient, CDAI, Safety, Pharmaceutical industry, UC, Roivant Sciences

The TAHOE study ( NCT05910528 ) is a global, randomized, double-blind study evaluating two doses of RVT-3101 given once-monthly in patients with moderate to severely active Crohn’s disease.

Key Points: 
  • The TAHOE study ( NCT05910528 ) is a global, randomized, double-blind study evaluating two doses of RVT-3101 given once-monthly in patients with moderate to severely active Crohn’s disease.
  • The primary and key secondary endpoints are the proportion of participants achieving clinical remission by Crohn's Disease Activity Index (CDAI) and the proportion of participants achieving endoscopic response at week 14.
  • This was the first-ever long-duration data reported for an anti-TL1A antibody.
  • Across all doses and patient groups, RVT-3101 was well tolerated and showed a favorable safety profile.